NBI-1117568
Key figures
Next catalyst
None scheduled
Only dates with a source are listed
Phase
Phase 3
Not recorded
Linked trials
4
From ClinicalTrials.gov
Latest FDA action
None on record
From Drugs@FDA
Recalls, shortages, patents and EU status at a glance
Key information
- Sponsor
- NEUROCRINE BIOSCIENCES INC NBIX Source: Company record for NEUROCRINE BIOSCIENCES INC (opens in a new tab)
- Indication
- Schizophrenia Source: Conditions from ClinicalTrials.gov (opens in a new tab)
- Designations
- None recorded
- Next catalyst
- None scheduled
Development timeline
- Preclinical Completed
- Phase 1 Completed
- Phase 2 Completed
- Phase 3 Current stageFirst trial start 8 May 20254 linked trials
- Filed Not yet
- Approved Not yet
Overview
- Mechanism
- Not recorded
- Route
- Not recorded
- Modality
- Not recorded
- Specialties
- Not recorded
Overview text is written by HealthTrade editors.
Key dates
No catalysts yet. Editors add each date together with its source.
FDA designations
No FDA designations are on record for NBI-1117568. Editors add each one with its source.
Filed application
No filed application is on record for NBI-1117568. Approvals are listed under FDA actions.
FDA advisory committees
No FDA advisory committee meetings are on record for NBI-1117568.
Clinical trials
| Trial | Title | Phase | Status | Enrollment | Primary completion | Results posted |
|---|---|---|---|---|---|---|
| NCT07227818ClinicalTrials.gov record for NCT07227818 (opens in a new tab) | Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia | Phase 3 | Recruiting | 560 (estimated) | Jul 2029 (estimated) | No |
| NCT07105098ClinicalTrials.gov record for NCT07105098 (opens in a new tab) | NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Phase 3 | Recruiting | 284 (estimated) | Nov 2027 (estimated) | No |
| NCT07114874ClinicalTrials.gov record for NCT07114874 (opens in a new tab) | NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia | Phase 3 | Recruiting | 600 (estimated) | Dec 2031 (estimated) | No |
| NCT06963034ClinicalTrials.gov record for NCT06963034 (opens in a new tab) | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Phase 3 | Recruiting | 284 (estimated) | Oct 2027 (estimated) | No |
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.
Trial quality
About CT-VCALoading trial quality…
FDA actions
No FDA approvals on record for this drug.
FDA recalls load here.
FDA drug shortages load here.
Orange Book patents load here.
FAERS adverse event counts load here.
Papers and preprints load here.
Community discussion loads here.
EU status (EMA)
EMA's medicines data lists no human medicine with the same active substance as NBI-1117568.
Source: European Medicines Agency (EMA), medicines data download.
Related news
No recent headlines mention this drug.
Sources
- ClinicalTrials.gov NCT07114874 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT07227818 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT07105098 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT06963034 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
Record updated .
Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.